Results 231 to 240 of about 13,388,827 (299)

Engineering Photothermal Nanoplatforms for Multimodal Theranostics and Biosensing

Rare Metals, Volume 45, Issue 10, October 2026.
ABSTRACT Photothermal platforms bridge materials science and biomedicine, emerging as a transformative frontier in biomedical applications. They offer spatiotemporally precise, noninvasive modalities with cell‐type‐independent efficacy for treating a range of diseases.
Xiao Han, Peng Jin, Haiqing Wang, Hao Xue   +3 more
wiley   +1 more source

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Journal of Diabetes, Volume 18, Issue 10, October 2026.
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke, Yinghong Kong, Songbo Fu, Liyun Wang, Ying Pan, Shao Zhong, Yanhua Jiang, Hui Chen, Xuehua Jiao, Fuxing Sha, Liwu Xu, Wei Shao, Fenghua Lan, Xiaoli Chen, Bo Yan, Guangju Zhou, Ping Shi, Fen Li, Huike He, Hong Li, Guangwu Zhang, Hongyu Duan, Fang Wang, Weikun Gong, Yuxiao Bai, Bin Wang, Xin Mou, Liying He, Wukun Ma, Junhua Song, Juan Zheng, Xiaosu Bai, Xiaosi Li, Xin Yan, Yanqiu Wang, Zhenhua Wang, Juan Yuan, Wei Lu, Yuan Liang, Yufan Wang, Fenjuan Xu, Xuefeng Li, Xuan Lin, Hongbin Zhu, Lingling Xu, Xiaojia Lou, Lingxiao Wang, Lijuan Cui, Lijun Wang, Hua Qian, Yuwen Shi, Yanbing Li   +51 more
wiley   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]

Diabetol Int
Miwa T, Yoshida S, Nakajima A, Koto R, Nishimura R.   +4 more
europepmc   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial. [PDF]

Diabetes Ther
Laffel LM.
europepmc   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9336-9345, October 2026.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source